Table 2.
Feedback given to WFO and the corresponding updated status.
| Feedback time | Suggestion | Updated time |
|---|---|---|
| 2017.3 | Apply adjuvant therapy to patient <80 y | 2017.3 |
| 2017.5 | Genetic analysis should be mandatory | 2017.5 |
| 2017.5 | Stage II: High-Risk Evaluation + MSI test should be added | MSI (2017.9) Risk Evaluation (2018.1) |
| 2017.5 | Add previous therapy details | 2017.5 |
| 2017.4 | NCCN/ESMO Guidelines should list as the top priority as well; classic publications recommended | Updated every 3 months |
| 2017.5 | Indication for neoadjuvant therapy: CRM/EMVI evaluation | 2017.9 |
| 2017.5 | RFA should be considered as a candidate option for mCRC treatment | IBM feedback pending |
| 2017.8 | Evaluation of pCR and NED should be added | IBM feedback pending |
MSI, Microsatellite instability; NCCN, National Comprehensive Cancer Network; ESMO, European Society for Medical Oncology; CRM, Circumferential resection margin; EMVI, Extramural vascular invasion; pCR, Pathological complete response; NED, No evidence of disease; RFA, Radio-frequency ablation; mCRC, Metastatic colorectal cancer.